The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Abstract
Objective: Striatal serotonin projections have been implicated in levodopa‐induced dyskinesia by providing an unregulated source of dopamine release. We set out to determine whether these projections are affected by levodopa treatment in a way that would favor the occurrence of dyskinesia. Methods: As an index of terminal serotonin innervation density, we measured radioligand binding to the plasma membrane serotonin transporter (SERT) in levodopa‐treated dyskinetic and nondyskinetic subjects, using brain tissue from both rat and monkey models of Parkinson disease as well as parkinsonian patients. In addition, striatal tissue from dyskinetic rats was used for morphological and ultrastructural analyses of serotonin axon terminals, and for studies of stimulated [3 H]dopamine release. Results: Across all conditions examined, striatal levels of SERT radioligand binding were significantly elevated in dyskinetic subjects compared to nondyskinetic cases. In the rat striatum, dyskinesiogenic levodopa treatment had induced sprouting of serotonin axon varicosities having a relatively high synaptic incidence. This response was associated with increased depolarization‐induced [3 H]dopamine release and with a stronger release potentiation by brain‐derived neurotrophic factor. Interpretation: This study provides the first evidence that L‐dopa treatment induces sprouting of serotonin axon terminals, with an increased incidence of synaptic contacts, and a larger activity‐dependent potentiation of dopamine release in the dopamine‐denervated striatum. Treatment‐induced plasticity of the serotonin innervation may therefore represent a previously unappreciated cause of altered dopamine dynamics. These results are important for understanding the mechanisms by which L‐dopa pharmacotherapy predisposes to dyskinesia, and for defining biomarkers of motor complications in Parkinsons disease. Ann Neurol 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders
Mattson, M. P., Maudsley, S., & Martin, B. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.001 · Cited by 942
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821 · cited 9×
“Studies in rats with nigrostriatal DA lesions have shown that ascending serotonin (5-hydroxytryptamine, 5- HT) projections from the midbrain raphe nuclei play a determinant role in LID.”
BackgroundSelf-citationDopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Bjorklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 636
BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization
Guillin, O., Diaz, J., Carroll, P., Griffon, N., Schwartz, J.-C., & Sokoloff, P. (2001) · Nature · doi:10.1038/35075076 · Cited by 574
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 571
Levodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478
de la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L.-J., Guttman, M., & Furukawa, Y. (2007) · Brain · doi:10.1093/brain/awm239 · Cited by 375
Andersson, M., Hilbertson, A., & Cenci, M. A. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0259 · Cited by 350
Self-citationMamounas, L. A., Altar, C. A., Blue, M. E., Kaplan, D. R., Tessarollo, L., & Lyons, W. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00771.2000 · Cited by 344
Cited by
Circuit Mechanisms of Parkinson’s Disease
McGregor, M. M., & Nelson, A. B. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.004 · Cited by 624
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Serotonin in Parkinson's disease
Politis, M., & Niccolini, F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.037 · Cited by 306
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Serotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00922-9 · Cited by 131
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018) · Movement Disorders · doi:10.1002/mds.27386 · Cited by 121
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease
Poewe, W., & Mahlknecht, P. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2019.12.002 · Cited by 60
Tronci, E., Napolitano, F., Muñoz, A., Fidalgo, C., Rossi, F., Björklund, A., Usiello, A., & Carta, M. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.017 · Cited by 57
Dopamine Modulates Serotonin Innervation in the Drosophila Brain
Niens, J., Reh, F., Çoban, B., Cichewicz, K., Eckardt, J., Liu, Y.-T., Hirsh, J., & Riemensperger, T. D. (2017) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2017.00076 · Cited by 38
“In vertebrate models of PD, degeneration of DA neurons leads to modifications in 5-HT neurons (Zhou et al., 1991; Rylander et al., 2010; Zeng et al., 2010; Niederkofler et al., 2015).”
BackgroundResultInfluentialDysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia
Vegas-Suarez, S., Paredes-Rodriguez, E., Aristieta, A., Lafuente, J. V., Miguelez, C., & Ugedo, L. (2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.06.013 · Cited by 26
Metadata
- Authors
- Rylander, D., Parent, M., O'Sullivan, S. S., Dovero, S., Lees, A. J., Bezard, E., Descarries, L., & Cenci, M. A.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-09-29
- Volume
- 68
- Issue
- 5
- Pages
- 619-628
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2112559108
- Cited by
- 262
- References
- 39
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.